SSY Group Limited 2005
HKEX · Hong Kong SAR China · Health Technology
HKD 2.77-0.06 (-2.12%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SSY Group (SEHK:2005) has just added two fresh approvals from China’s National Medical Products Administration to its portfolio, covering antipsychotic active ingredients and a perioperative antiviral injection used around stem cell transplants. SSY Group’s latest approvals arrive after a strong 90-day share price return of 26.5%, building on a 10.9% move over the past month, even though the year-to-date share price return is down 4.02% and the 3-year total shareholder return has fallen...
As global markets navigate through geopolitical uncertainties and central banks hold interest rates steady, investors are increasingly looking towards Asia for unique opportunities. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or newer companies that can offer surprising value. With solid financial foundations and potential for growth, these stocks might present compelling opportunities in today’s market landscape.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.